PT  - JOURNAL ARTICLE
AU  - Hori, Kensuke
AU  - Morikawa, Nagisa
AU  - Tayama, Eiki
AU  - Fukumoto, Yoshihiro
TI  - Safety of anti-thrombotic therapy in acute aortic dissection; single center, observational study
AID  - 10.1101/2022.05.18.22275251
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.18.22275251
4099  - http://medrxiv.org/content/early/2022/05/21/2022.05.18.22275251.short
4100  - http://medrxiv.org/content/early/2022/05/21/2022.05.18.22275251.full
AB  - Background Acute aortic dissection occurs due to a primary tear in aortic intima, with blood from aortic lumen penetrating into diseased media, in which anti-thrombotic therapies may be harmful. We examined the prognosis in patients, who had already taken antithrombotic therapies at the onset of acute aortic dissection, and the safety to administer anti-thrombotic drugs in acute phase during hospitalization.Methods and Results We retrospectively enrolled 685 patients with acute aortic dissection (type A/B: 454/231), who were transferred to Kurume University Hospital from 2004 to 2020. In both type A and B, there were no significant differences in in-hospital mortality between with and without antithrombotic therapies at the onset. Patients, who survived more than a day and administered anti-thrombotic drugs during hospitalization, had significantly lower in-hospital mortality than those who had no anti-thrombosis in acute phase in type A, while there was no significant difference in in-hospital mortality between the 2 groups in type B.Conclusions We demonstrated that anti-thrombotic drugs did not worsen the prognosis in patients with acute aortic dissection, indicating that we should not hesitate anti-thrombotic drugs if indicated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present study was approved by the institutional review board at Kurume University (21280).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableAll relevant data are within the manuscript and its Supporting Information files.